For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.

Pfizer expanded its cost-cutting plans and posted first-quarter profit above estimates, despite a decline in sales driven by falling revenue from its Covid pill, according to CNBC. The company ...

Pfizer (NYSE:PFE) surged about 3% on Tuesday ... Management reaffirmed its full-year 2025 outlook, noting that the forecast does not currently include any potential impact related to future ...

Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, "which we are unable to predict at this time." ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

MADRID, May 12 (Reuters) - Grifols's net profit almost tripled from a year earlier, which the Spanish drugmaker said ...

Pfizer on Tuesday expanded its cost-cutting efforts and reported first-quarter profit that topped ... Pfizer did not revise its outlook. The company maintained its full-year 2025 outlook ...